Both tirzepatide and semaglutide help with weight loss and blood sugar control, but they work in different ways. Tirzepatide acts on two gut hormones (GLP-1 and GIP). Semaglutide acts on one (GLP-1). In a head-to-head trial of the FDA-approved branded versions, tirzepatide led to greater weight loss on average, though results vary from person to person.

Both are well studied and effective. Most side effects show up during dose increases and tend to fade. For a broader look at this medication class, see Testing.com’s guide to GLP-1 agonists.

How Tirzepatide and Semaglutide Work

Semaglutide is a GLP-1 receptor agonist. GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after you eat. It tells your brain you’re full, slows how fast your stomach empties, and helps control blood sugar. Semaglutide copies this hormone so its effects last longer.

Tirzepatide is a dual GLP-1/GIP receptor agonist. It copies both GLP-1 and a second gut hormone called GIP (glucose-dependent insulinotropic polypeptide). GIP helps with insulin release and fat burning. By working on both pathways, tirzepatide may have broader effects than GLP-1 alone.

You take both as once-weekly shots under the skin. Prescribers start at a low dose and raise it slowly over several weeks (called titration) to reduce side effects. The FDA-approved branded version of semaglutide also comes as a daily pill for type 2 diabetes.

The dual-action design is the key difference. Whether it matters for you depends on your health, your goals, and how your body responds.

Compounded tirzepatide and compounded semaglutide are not FDA-approved finished drug products. For more on each medication individually, see Testing.com’s guides to compounded semaglutide and compounded tirzepatide.

Weight Loss: What the Clinical Trials Show

Trials of the FDA-approved branded versions give the clearest look at how these two drugs compare.

Head-to-head data

The SURMOUNT-5 trial put the FDA-approved branded version of tirzepatide up against the FDA-approved branded version of semaglutide in adults with obesity. At 72 weeks, people taking tirzepatide lost an average of 20.2% of their body weight. Those taking semaglutide lost 13.7%.

Tirzepatide trials

In the SURMOUNT-1 trial, participants taking the highest dose (15 mg) of the FDA-approved branded version of tirzepatide lost an average of 22.5% of body weight at 72 weeks. The SURPASS-2 trial was a head-to-head comparison against semaglutide 1 mg (the maximum diabetes dose at the time), added on to metformin, in people with type 2 diabetes. It showed A1C reductions of roughly 2% to 2.5% depending on dose.

Semaglutide trials

In the STEP-1 trial, participants taking the FDA-approved branded version of semaglutide lost an average of 14.9% of body weight at 68 weeks. The SUSTAIN and SELECT trials showed meaningful A1C reductions and, in the SELECT trial, a reduction in major cardiovascular events in adults with established heart disease and obesity.

What these numbers mean for you

These are averages from large trials. Your results may differ based on your starting weight, health, dose, diet, and activity level. All trial data comes from the FDA-approved branded versions, not compounded forms.

Side Effects and Safety

Most people who take tirzepatide or semaglutide have some side effects, especially in the first weeks and after dose increases. These effects are usually short-lived.

Common side effects

Both drugs share a similar side effect profile. The most common effects include:

  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Stomach pain
  • Decreased appetite

These symptoms tend to improve as your body adjusts. A prescriber may recommend dietary changes (smaller meals, avoiding high-fat foods) or a short course of anti-nausea medication such as ondansetron to help manage GI side effects during dose increases.

Serious but less common risks

While uncommon, both medications carry risks that call for medical attention:

  • Pancreatitis: Severe stomach pain that spreads to your back may mean your pancreas is inflamed. Seek care right away.
  • Gallbladder problems: Gallstones have been reported in trials of both drugs.
  • Kidney injury: Ongoing vomiting or diarrhea can cause dehydration and kidney stress. Stay hydrated, and tell your prescriber if symptoms persist.
  • Hypoglycemia: Risk increases if you also take insulin or sulfonylureas. Your prescriber may adjust those doses.
  • Severe GI problems: Lasting vomiting, severe bloating, or not being able to pass stool can signal gastroparesis or bowel obstruction. Get medical help right away.

Boxed warning: thyroid C-cell tumors

Both drugs carry an FDA boxed warning about thyroid C-cell tumors. In animal studies, they caused these tumors in rodents. It is not known whether tirzepatide or semaglutide causes thyroid C-cell tumors in humans. Neither drug should be used by people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN2).

Drug interactions

Both drugs can interact with other medicines. Key ones to know:

  • Insulin and sulfonylureas: Increased risk of hypoglycemia. Dose adjustments may be needed.
  • Oral contraceptives: GLP-1 medications slow gastric emptying, which may reduce absorption of oral birth control pills. This matters most for tirzepatide: the FDA label advises switching to a non-oral contraceptive or adding a barrier method for 4 weeks after starting tirzepatide and for 4 weeks after each dose increase. This interaction is not considered clinically significant for semaglutide.
  • Oral medications: Slower gastric emptying can affect how quickly your body absorbs other pills. Talk to your prescriber about timing.

Surgery, Pregnancy, and Other Considerations

Surgery and anesthesia

If you take a GLP-1 drug and need surgery or any procedure with sedation, tell your anesthesiologist. Both tirzepatide and semaglutide cause delayed gastric emptying, so food may stay in your stomach longer than usual. This raises the risk of aspiration (breathing in stomach contents) during anesthesia. Your surgical team may give you specific fasting rules or ask you to adjust your dose before the procedure.

Pregnancy and contraception

Semaglutide is not recommended during pregnancy. The label for the FDA-approved branded version says to stop it at least two months before a planned pregnancy. Animal studies have shown risks, and human pregnancy data is limited.

GLP-1 medications slow gastric emptying, which may reduce absorption of oral contraceptives. If you rely on birth control pills, talk to your prescriber about whether a backup method is needed.

Tirzepatide also lacks sufficient human pregnancy data and, like semaglutide, should be stopped before a planned pregnancy. If you are pregnant or planning to become pregnant, discuss your options with your prescriber before starting or continuing either medication.

Labs That Help You Monitor Your Health on These Medications

Lab tests give you and your prescriber a clearer picture of how your body responds to treatment. Some tests can catch side effects early. Others track your progress over time.

Lab tests to consider first

Before starting a GLP-1 drug, your prescriber may order baseline labs to check your overall health:

  • A1C (hemoglobin A1C): Shows your average blood sugar over the past two to three months. Gives your prescriber a baseline to measure improvement.
  • Lipid panel: Checks cholesterol and triglyceride levels before treatment begins.
  • Comprehensive metabolic panel: Includes creatinine and other markers that check kidney function.
  • Lipase: Establishes a baseline level to compare if pancreatitis symptoms arise later.
  • Thyroid panel: Given the boxed warning about thyroid tumors, baseline thyroid testing gives your prescriber a starting point.

Labs to recheck on therapy

Once you begin treatment, periodic lab work helps confirm the drug is working and flags any concerns:

  • A1C: Recheck every three to six months to track blood sugar control over time.
  • Lipid panel: Repeat periodically to monitor cholesterol and triglyceride changes.
  • Comprehensive metabolic panel: Helps spot kidney stress from dehydration caused by nausea or vomiting.
  • Lipase: High levels can be an early sign of pancreatitis, a rare but serious side effect of both drugs.

Your prescriber will decide which tests to order and how often to repeat them based on your health history and treatment plan.

How to Get Started

Choosing between tirzepatide and semaglutide is a conversation to have with a prescriber who knows your health history. Baseline lab work can help guide that talk and give you a starting point to measure progress. You can learn more about available treatment options at Testing.com’s treatments page.

Frequently Asked Questions

Which is more effective for weight loss, tirzepatide or semaglutide?

In the SURMOUNT-5 head-to-head trial, the FDA-approved branded version of tirzepatide produced greater average weight loss than the FDA-approved branded version of semaglutide. Individual results depend on dose, health profile, and lifestyle factors.

What are the most common side effects of tirzepatide and semaglutide?

Both can cause nausea, vomiting, diarrhea, and constipation, especially during dose increases. These effects are usually temporary.

Can you switch from semaglutide to tirzepatide?

Yes, switching is possible under medical supervision. Your prescriber will adjust your dose and monitor for side effects during the transition.

Do tirzepatide and semaglutide help with type 2 diabetes?

Yes. Both medications lower A1C and improve blood sugar control. Clinical trials of the FDA-approved branded versions have shown meaningful A1C reductions.

What lab tests should you get before starting a GLP-1 medication?

Common baseline tests include A1C, a lipid panel, a comprehensive metabolic panel, lipase, and thyroid function tests. Your prescriber will recommend the right panel based on your health history.

Sources

See More